12,150 Shares in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Purchased by Choreo LLC

Choreo LLC bought a new stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 12,150 shares of the specialty pharmaceutical company’s stock, valued at approximately $396,000.

Several other hedge funds have also made changes to their positions in COLL. Gladius Capital Management LP acquired a new position in Collegium Pharmaceutical in the second quarter valued at approximately $32,000. Principal Securities Inc. acquired a new position in shares of Collegium Pharmaceutical in the 4th quarter valued at $40,000. nVerses Capital LLC grew its holdings in shares of Collegium Pharmaceutical by 1,600.0% during the 2nd quarter. nVerses Capital LLC now owns 1,700 shares of the specialty pharmaceutical company’s stock worth $55,000 after purchasing an additional 1,600 shares during the period. Sheaff Brock Investment Advisors LLC purchased a new position in shares of Collegium Pharmaceutical during the 1st quarter worth $204,000. Finally, Assetmark Inc. increased its position in shares of Collegium Pharmaceutical by 25.5% during the 4th quarter. Assetmark Inc. now owns 5,445 shares of the specialty pharmaceutical company’s stock worth $168,000 after purchasing an additional 1,108 shares during the last quarter.

Wall Street Analyst Weigh In

COLL has been the topic of a number of recent analyst reports. Piper Sandler reaffirmed a “neutral” rating and issued a $37.00 target price (down previously from $39.00) on shares of Collegium Pharmaceutical in a research report on Friday, August 9th. Truist Financial upped their target price on shares of Collegium Pharmaceutical from $40.00 to $42.00 and gave the company a “buy” rating in a research report on Friday, August 9th. HC Wainwright upped their target price on shares of Collegium Pharmaceutical from $47.00 to $50.00 and gave the company a “buy” rating in a research report on Thursday, September 5th. Needham & Company LLC reaffirmed a “hold” rating on shares of Collegium Pharmaceutical in a research report on Friday, August 9th. Finally, StockNews.com cut shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 31st. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, Collegium Pharmaceutical has an average rating of “Moderate Buy” and a consensus target price of $42.60.

Insider Activity at Collegium Pharmaceutical

In related news, EVP Shirley R. Kuhlmann sold 19,248 shares of the firm’s stock in a transaction that occurred on Thursday, September 5th. The shares were sold at an average price of $38.30, for a total value of $737,198.40. Following the sale, the executive vice president now owns 120,161 shares of the company’s stock, valued at $4,602,166.30. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 3.98% of the stock is owned by corporate insiders.

Collegium Pharmaceutical Stock Down 1.0 %

Shares of COLL opened at $37.11 on Tuesday. The stock has a market capitalization of $1.20 billion, a PE ratio of 15.46 and a beta of 0.94. Collegium Pharmaceutical, Inc. has a 1 year low of $20.95 and a 1 year high of $40.95. The company has a debt-to-equity ratio of 1.71, a quick ratio of 1.04 and a current ratio of 1.11. The company’s 50-day simple moving average is $35.54 and its 200-day simple moving average is $35.41.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its quarterly earnings results on Thursday, August 8th. The specialty pharmaceutical company reported $1.62 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.40 by $0.22. The business had revenue of $145.28 million for the quarter, compared to analysts’ expectations of $143.94 million. Collegium Pharmaceutical had a net margin of 17.32% and a return on equity of 107.62%. The business’s quarterly revenue was up 7.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.13 earnings per share. Analysts forecast that Collegium Pharmaceutical, Inc. will post 5.82 earnings per share for the current fiscal year.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.